Atlas Trials

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

Clinical trial NCT06519344 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06519344
Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
B Cell Malignancies
Start date
2024-07-31
Primary completion
2026-07-30
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.